


PHARMACEUTICAL 2019

Allergan plc Rank 122 of 363





PHARMACEUTICAL 2019

Allergan plc Rank 122 of 363

The relative strengths and weaknesses of Allergan plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Allergan plc compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 266% points. The greatest weakness of Allergan plc is the variable Other Liabilities, reducing the Economic Capital Ratio by 100% points.

The company's Economic Capital Ratio, given in the ranking table, is 154%, being 117% points above the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	6,475,400
Cost of Goods Sold	2,191,400
Intangible Assets	89,608,700
Liabilities, Current	5,727,900
Liabilities, Non-Current	882,000
Other Assets	3,916,500
Other Compr. Net Income	-522,700
Other Expenses	14,535,500
Other Liabilities	30,046,700
Other Net Income	-609,300
Other Revenues	15,787,400
Property and Equipment	1,787,000
Research and Development	2,266,200
Selling, General and Administrative Expense	1,271,200

Output Variable	Value in 1000 USD
Assets	101,787,600
Liabilities	36,656,600
Expenses	20,264,300
Revenues	15,787,400
Stockholders Equity	65,131,000
Net Income	-5,086,200
Comprehensive Net Income	-5,347,550
Economic Capital Ratio	154%

